Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Acrivon Therapeutics (Nasdaq: ACRV) reported its financial results for Q4 and FY 2022, highlighting a net loss of $8.9 million for Q4 and $31.2 million for the full year, compared to losses of $4.3 million and $16.2 million in 2021.
The company successfully completed its IPO in November 2022 and initiated a Phase 2 trial for ACR-368 in patients with platinum-resistant cancers. Acrivon aims to advance precision oncology through its OncoSignature test and has made significant progress, including partnerships and team expansions. As of December 31, 2022, it had $169.6 million in cash, expected to fund operations through Q4 2024.
- Successful IPO on Nasdaq in November 2022.
- FDA clearance for ACR-368's Phase 2 trial with registrational intent.
- Strong cash position of $169.6 million to fund operations into Q4 2024.
- Net loss increased to $31.2 million in FY 2022 from $16.2 million in FY 2021.
- R&D expenses surged to $23.9 million in FY 2022 from $13.7 million in FY 2021.
WATERTOWN, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the fourth quarter and full year ended December 31, 2022 and reviewed business highlights.
“The mission of Acrivon is to pioneer a new era of precision oncology, and 2022 was an important year for us,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. “Amongst our many achievements, we are particularly excited about our successful IPO on NASDAQ and the FDA clearance and subsequent initiation of our potentially registrational Phase 2 trial with ACR-368 in patients with platinum-resistant ovarian, endometrial, and bladder cancer. Our team is fully focused on both the clinical execution of this trial as well as the advancement of our preclinical programs targeting WEE1 and PKMYT1, leveraging our differentiated proteomics-based precision medicine platform across all our pipeline programs. Our landmark Phase 2 study is the first to stratify patients based on predicted sensitivity to ACR-368 using our proprietary OncoSignature test. Acrivon’s predictive precision proteomics platform, AP3, has the potential to transform precision medicine and overcome the limitations of traditional genetics-based biomarker approaches for patient responder identification to improve treatment outcomes for patients.”
Business Highlights
- Acrivon is advancing precision oncology medicines through the utilization of drug-specific proteomics-based OncoSignature® tests, a first-of-its-kind companion diagnostic used to identify the patients most likely to benefit from a drug candidate.
- The company believes proteomic biomarkers have the potential to be broadly applicable for the vast majority of cancers where genetics-based approaches have proven challenging.
- OncoSignature tests are developed utilizing Acrivon’s Predictive Precision Proteomics (AP3) platform, which has the ability to match the drug mechanism of action with the critical tumor-driving pathways, and identify new indications, resistance mechanisms, and rational drug combinations.
- The lead drug candidate ACR-368, also known as prexasertib, targeting CHK1 and CHK2 is being advanced in a multicenter, open-label Phase 2 clinical trial with single-arm, potentially registrational cohorts of patients with platinum-resistant ovarian cancer, endometrial adenocarcinoma, and urothelial cancers based on predicted sensitivity to ACR-368.
- In past Phase 2 clinical trials, ACR-368 has been administered to more than 400 patients at the recommended Phase 2 dose (RP2D) with reported deep, durable monotherapy responses, including complete responses, observed in a proportion of patients with solid tumors, including platinum-resistant ovarian cancer.
- The OncoSignature test has been extensively evaluated in preclinical studies, including in blinded, prospectively designed studies on pretreatment tumor biopsies collected from past clinical trials with ACR-368 in platinum-resistant ovarian cancer, demonstrating the ability to predict responders to ACR-368.
- The ACR-368 OncoSignature test has also been used for screening across human intended use processed cancer tissues to identify endometrial and bladder cancers as predicted sensitive tumor types, which was subsequently confirmed in genetically non-modified patient-derived xenograft models of these two tumor types.
- In addition to ovarian cancer, ACR-368 has also demonstrated single agent deep, durable responses in patients with squamous cell cancer of the head and neck and with anal cancer at RP2D, and Acrivon holds an orphan drug designation granted for ACR-368 in anal cancer.
- A preclinical pipeline targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase, is being advanced leveraging the AP3 platform.
Accomplishments
- Completed successful Initial Public Offering; Shares began trading on the Nasdaq Global Market on November 15, 2022 under the ticker symbol “ACRV”
- Received clearance by the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its lead asset ACR-368 in a Phase 2 master protocol trial at RP2D with registrational intent to treat patients with ovarian, endometrial and urothelial cancers, a first-of-its-kind trial based on OncoSignature-predicted sensitivity to ACR-368
- Executed partnership with Akoya Biosciences to co-develop, validate, and commercialize Acrivon’s OncoSignature test
- Strengthened management team with exceptional hires, including: Rasmus Holm-Jorgensen, chief financial officer; Mary-Alice Miller, general counsel; Praveen Marapaka, Ph.D., senior vice president of global regulatory affairs; Monica Phadnis, vice president of clinical operations; Dominic Lai, M.D., vice president of clinical development; Bruce Close, vice president of quality and compliance; James P. Dunyak, Ph.D., vice president of biostatistics; Joon Jung, Ph.D., vice president and head of data science; Thomas P. Nifong, M.D., head of clinical CDx operations; Sam Rua, vice president of CDx regulatory; John van Duzer, Ph.D., vice president of CMC; Katharine Peterson, C.P.A., vice president of finance and accounting; and David Proia, Ph.D., vice president of biology and drug discovery
Anticipated Upcoming Milestones
- Report initial clinical data from the Phase 2, multicenter, open-label ACR-368 trial in patients with platinum-resistant ovarian, endometrial, and urothelial cancers during the second half of 2023
- Advance one or both of our WEE1 and PKMYT1 inhibitor programs targeting critical nodes in the DNA Damage Response pathways into IND-enabling studies during 2023
- Option to initiate one or more clinical trials under the same or a similar trial protocol design in patients with one or more of three additional cancer types, including human papilloma virus-positive squamous cell carcinomas, such as squamous cell cancer of the head and neck, anal, and cervical cancers
Fourth Quarter and Full Year 2022 Financial Results
Net loss for the quarter and full year ended December 31, 2022 was
Research and development expenses were
General and administrative expenses were
As of December 31, 2022, the company had cash, cash equivalents and marketable securities of
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature® companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. Acrivon’s ACR-368 OncoSignature® test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third party Phase 2 trials in patients with ovarian cancer treated with ACR-368. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs targeting two critical nodes in the DNA Damage Response, or DDR, including WEE1, a protein serine/threonine kinase, and the closely related PKMYT1.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts:
Alexandra Santos
asantos@wheelhouselsa.com
Aljanae Reynolds
areynolds@wheelhouselsa.com
| Acrivon Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) | ||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Research and development | $ | 5,862 | $ | 3,053 | $ | 23,949 | $ | 13,718 | ||||||||||
| General and administrative | 4,083 | 1,217 | 8,708 | 2,466 | ||||||||||||||
| Total operating expenses | 9,945 | 4,270 | 32,657 | 16,184 | ||||||||||||||
| Loss from operations | (9,945 | ) | (4,270 | ) | (32,657 | ) | (16,184 | ) | ||||||||||
| Other income (expense): | ||||||||||||||||||
| Other income (expense), net | 1,016 | (17 | ) | 1,490 | 21 | |||||||||||||
| Change in fair value of preferred stock tranche rights | - | - | - | (50 | ) | |||||||||||||
| Change in fair value of anti-dilution right | - | (56 | ) | - | (30 | ) | ||||||||||||
| Total other income (expense), net | 1,016 | (73 | ) | 1,490 | (59 | ) | ||||||||||||
| Net loss | $ | (8,929 | ) | $ | (4,343 | ) | $ | (31,167 | ) | $ | (16,243 | ) | ||||||
| Net loss per share - basic and diluted | $ | (0.80 | ) | $ | (2.45 | ) | $ | (7.56 | ) | $ | (9.32 | ) | ||||||
| Weighted-average common stock outstanding - basic and diluted | 11,093,563 | 1,769,561 | 4,121,912 | 1,743,382 | ||||||||||||||
| Comprehensive loss: | ||||||||||||||||||
| Net loss | $ | (8,929 | ) | $ | (4,343 | ) | $ | (31,167 | ) | $ | (16,243 | ) | ||||||
| Other comprehensive loss: | ||||||||||||||||||
| Unrealized gain (loss) on available-for-sale investments, net of tax | 38 | - | (95 | ) | - | |||||||||||||
| Comprehensive loss | $ | (8,891 | ) | $ | (4,343 | ) | $ | (31,262 | ) | $ | (16,243 | ) | ||||||
| Acrivon Therapeutics, Inc. Condensed Consolidated Balance Sheets (in thousands) | |||||||||
| December 31, | |||||||||
| 2022 | 2021 | ||||||||
| Assets | |||||||||
| Cash and cash equivalents | $ | 29,519 | $ | 99,603 | |||||
| Short-term investments | 98,232 | - | |||||||
| Long-term investments | 41,881 | - | |||||||
| Other assets | 11,594 | 6,984 | |||||||
| Total assets | $ | 181,226 | $ | 106,587 | |||||
| Liabilities and Stockholders' Equity (Deficit) | |||||||||
| Liabilities | 10,751 | 7,878 | |||||||
| Convertible preferred stock | - | 122,518 | |||||||
| Stockholders' Equity (Deficit) | 170,475 | (23,809 | ) | ||||||
| Total Liabilities and Stockholders' Equity (Deficit) | $ | 181,226 | $ | 106,587 | |||||
FAQ
What were Acrivon Therapeutics' financial results for Q4 2022 and FY 2022?
What is ACR-368 and its significance for Acrivon?
When did Acrivon Therapeutics go public?
What financial position does Acrivon hold as of December 31, 2022?
What are the anticipated milestones for Acrivon in 2023?
